Data collection and analysis
The authors independently assessed all search results for eligibility. No eligible trials were identified for inclusion.
Main results
No current published eligible trials were identified, although three ongoing clinical trials are likely to be eligible for inclusion in future updates of this review.
Authors' conclusions
We did not identify any randomised trials which would allow us to make any evidence-based recommendations. Although the results of several non-randomised studies would suggest that, once isolated, the eradication of MRSA is possible; whether this has a significant impact on clinical outcome is still unclear. Further research is required to guide clinical decision making in the management of MRSA infection in cystic fibrosis.
P L A I N L A N G U A G E S U M M A R Y

Interventions to clear meticillin-resistant Staphylococcus aureus (MRSA) from the lungs of people with cystic fibrosis
Review question
We looked for evidence to determine the effect of different ways of clearing meticillin-resistant Staphylococcus aureus (MRSA) from the lungs of people with cystic fibrosis. (MRSA) , is the name given to a particular bacteria which is resistant to some types of antibiotics. This is particularly worrying for people with cystic fibrosis, which is an inherited condition that causes thick mucus to build up in the lungs. It is very difficult for people with cystic fibrosis to cough up this thick mucus, making it an ideal breeding ground for bacteria, including MRSA, and making these people more prone to chest infections. It is thought that MRSA can cause more damage than other bacteria which are not resistant to antibiotics. We wanted to identify research evidence to support the best way for treating MRSA infections and also to see if this would improve the lives of people with cystic fibrosis.
Background
Meticillin-resistant Staphylococcus aureus
Search date
The evidence is current to: 04 September 2014.
Key results
Unfortunately, we could not find any trials which compared treating MRSA to not treating MRSA, or which compared one form of treatment to another. We are unable, therefore, to make any recommendations for its management at this point in time.
B A C K G R O U N D Description of the condition
Cystic fibrosis (CF) is the most common autosomal inherited condition in the Caucasian population, with a gene carrier rate of 1 in 25 and affecting around 1 in 2500 newborns in the UK (CF Trust UK 2011) . It is a multisystem disorder resulting from a disruption in chloride transport at the cellular level leading to abnormal, dehydrated secretions within the lungs. This results in impaired mucociliary clearance leading to recurrent pulmonary infections, bronchiectasis and progressively deteriorating lung function, which is the main cause of the morbidity and mortality seen in CF.
Organism
The abbreviation MRSA stands for meticillin-resistant Staphylococcus aureus (S. aureus). Meticillin is an antibiotic that is no longer in clinical use, but MRSA is resistant to antibiotics within the same class. This includes flucloxacillin, which is prescribed both for prophylaxis and treatment of infection with S. aureus in people with CF in the UK. Furthermore, MRSA is also resistant to other antibiotics in the beta lactam family such as cephalosporins (e.g. ceftazidime) and carbapenems (e.g. meropenem). Resistance is not due to production of beta lactamase enzymes, but rather to the production of altered penicillin-binding proteins coded on the mecA gene. Most MRSA infections in both the non-CF and CF populations have been so-called 'healthcare associated' (HA-MRSA), which occur in patients who have been hospitalised, had surgery, are on dialysis, or who have had invasive procedures. However, in recent years outbreaks of 'community-acquired' MRSA (CA-MRSA) have occurred in otherwise healthy people with no link to a healthcare facility (Chambers 2009 ). This distinction by patient location at time of infection is becoming increasingly difficult, given outbreaks of strains of CA-MRSA in hospitals, and the spread of HA-MRSA strains in the community through people with chronic illnesses. It is possible to further classify MRSA according to the staphylococcal chromosome cassette mec (SCCmec) type, on which the mecA gene is located. Several distinct types have been described to date, of which HA-MRSA is associated with types I to III. These SCCmec types also encode for resistance to other classes of antibiotics, thus making HA-MRSA overall more resistant. So-called CA-MRSA carries SCCmec types IV and V. Although CA-MRSA usually has the smaller type IV SCCmec type, which lacks some of the antibiotic resistance determinants possessed by types I to III, it is also more frequently associated with the production of the virulence factor Panton-Valentine leucocidin (PVL), a cytotoxin which causes leucocyte destruction and tissue necrosis. Although patients with MRSA have been found to require a higher intensity of treatment when compared with their meticillin-sensitive S. aureus (MSSA) counterparts, this is further complicated by differences observed between different MRSA types (Muhlebach 2011). For instance, the emergence of PVL-positive CA-MRSA within the CF population has been described and one report suggests this to be associated with a more severe clinical course acutely compared with PVL-negative CA-or HA-MRSA strains (Elizur 2007).
Prevalence
The prevalence of MRSA varies throughout Europe. As reported by the European Centre for Disease Prevention and Control, in the UK 25% to 50% of isolates of S. aureus are found to be MRSA compared to less than 1% in Norway (ECDC 2009 
Condition
As described above, one of the early key pathogens in CF-lung disease is MSSA, but increasingly MRSA has been cultured from the lower respiratory tracts of people with CF. The role of MRSA in CF-lung disease remains debated. A large observational study looking at 1834 patients who had positive respiratory cultures for S. aureus (MRSA or MSSA) found that presence of MRSA in respiratory cultures was associated with poorer lung function, more courses of antibiotics and longer hospital stays when compared with those colonised with MSSA (Ren 2007). However, the authors were unable to conclude whether their findings were due to cause or effect. Two studies were published in 2008 addressing this point, but came to differing conclusions (Dasenbrook 2008; Sawicki 2008) . Dasenbrook suggested that chronic, though not intermittent, detection of MRSA in respiratory tract cultures of people with CF (as defined by reports from the CF Foundation Registry) is associated with poorer survival and reduced lung function (Dasenbrook 2008; Dasenbrook 2010) . By contrast, Sawicki concluded that although MRSA was a marker for more aggressive therapy and may reflect increased disease severity, MRSA detection was not associated with a significant decline in lung function (Sawicki 2008). Although both were longitudinal studies, Sawicki analysed data from an observational study of people with CF in North America (Epidemiologic Study of Cystic Fibrosis (ESCF) (Morgan 1999)) using multivariate linear regression analysis to study the impact of MRSA on lung function (forced expiratory volume in one second (FEV 1 ) per cent (%) predicted); whilst Dasenbrook used data from the CF Foundation Registry. One of the fundamental differences between the two studies is the inclusion criteria. Sawicki included patients for analysis who had only one positive culture for MRSA (23% of cohort) whilst Dasenbrook studied patients with three or more positive cultures, those with one or two MRSA cultures were excluded. Despite these differences, both studies reported an increased rate of decline in FEV 1 % predicted of around 0.5% in their 'before' and 'after' MRSA groups. It is possible that this did not reach statistical significance in the Sawicki paper secondary to the smaller cohort size (593 versus 1732). An increased rate of decline of 0.8% has more recently been reported by a group in Belgium who conducted a retrospective case-control study based at a single centre (Vanderhelst 2012) . In terms of survival, Dasenbrook found that detection of MRSA from the respiratory tract of CF patients was associated with a risk of death 1.27 (95% confidence interval (CI) 1.11 to 1.45) times that of individuals in whom MRSA had never been detected (Dasenbrook 2010). Perhaps of more clinical importance however, is that they also found that patients who clear MRSA within one year have the same risk of death as those who never have a positive culture for MRSA. This emphasizes the importance and need for clear guidance on how we manage MRSA infection in CF.
Description of the intervention
Currently in the UK, children are prescribed prophylactic antistaphylococcal antibiotics (flucloxacillin) from diagnosis until three years of age with resultant fewer isolates of S. aureus, though the clinical significance of this finding remains uncertain (Smyth 2003) . However, the US Cystic Fibrosis Foundation recommend against the use of prophylaxis in anticipation that this may lead to an increase in colonisation of Pseudomonas aeruginosa (P. aeruginosa) (Flume 2007) . Some authors suggest a pragmatic approach would be to treat every isolate of MRSA or MSSA with eradication therapy (Solis 2003). However, this approach, with its frequent use of antibiotics, would run the risk of increasing the incidence of multi-resistant organisms that are less susceptible to treatment, whilst potentially adding to the already substantial treatment burden that people with CF face. Certainly in the case of HA-MRSA infections, there has been encouraging progress since the introduction of stringent MRSA screening and eradication measures in hospitals 
Why it is important to do this review
Despite the increasing prevalence of MRSA, its clinical significance remains unclear and there remains no international consensus for its management. With the increasing prevalence of resistant strains of S. aureus, it becomes more important for any therapeutic approaches with antibiotics to be justified with the most up-to-date evidence, especially in patients with chronic medical conditions. A previous Cochrane review could not find enough evidence to support the use of any single or combination of therapies for eradicating nasal or extra-nasal colonisation of MRSA over another (Loeb 2003) . Most studies addressing MRSA colonisation have been done in either healthy carriers or people in chronic care facilities, but not in those with chronic lung disease as seen in CF. Such reports include a variety of interventions, often focusing on nasal and skin colonisation, thus such findings may not be directly applicable to CF. However, a retrospective review of MRSA eradication practice in a single large UK adult CF centre showed some promise (Doe 2010). They used varying eradication regimes based on sensitivity patterns and individual tolerability, including stringent patient segregation and topical decolonisation, to attempt MRSA eradication from sputum and skin in CF patients. Over a 10-year period they reported an eradication rate of 81% (defined as three consecutive negative sputum and peripheral cultures over six months), though the clinical impact of what successful MRSA eradication meant for patients was not reported. The 2008 UK CF Trust consensus statement document stated that in the absence of prospective randomised clinical trials looking at the effect on lung function which chronic carriage with MRSA confers, MRSA infection will lead to a reduction in antibiotic treatment options and a likelihood of a deterioration in lung function. It is therefore their recommendation that the eradication of MRSA should be attempted for positive cases (CF Trust 2008). The rationale for this review is to determine the success of MRSA eradication for people with CF, and to question whether eradication confers improved clinical outcomes. This version of the review is an update of the original review (Lo 2013).
O B J E C T I V E S
To evaluate the effectiveness of treatment regimens designed to eradicate MRSA and to determine whether the eradication of MRSA confers better clinical and microbiological outcomes for patients with CF.
To ascertain whether attempts at eradicating MRSA can lead to increased acquisition of other resistant organisms (including P. aeruginosa) or increased adverse effects from drugs, or both.
M E T H O D S Criteria for considering studies for this review Types of studies
Randomised or quasi-randomised controlled trials.
Types of participants
Children and adults diagnosed with CF clinically and by sweat or genetic testing with a confirmed positive microbiological isolate of MRSA on clinically relevant CF respiratory cultures (bronchoalveolar lavage (BAL), cough or oropharyngeal swab, spontaneous or induced sputum culture) specimen prior to enrolment into the trial. We included all disease severities. We did not include patients with nasal carriage of MRSA alone in this review.
Types of interventions
Any combinations of topical, inhaled, oral or intravenous antimicrobials with the primary aim of eradicating MRSA once detected on clinically relevant CF respiratory cultures compared with placebo, standard treatment or no treatment. 
Types of outcome measures
Searching other resources
We will also contact primary authors and research institutions of any future identified trials for unpublished data.
Data collection and analysis
We were unable to identify any eligible and completed trials for inclusion in this review. We have detailed our methodology for selection of trials and also the planned methodology for data analysis should eligible studies become available in future searches.
Selection of studies
Two authors (DL, MH) independently screened trials for inclusion in this review using methods in accordance with methods described by Higgins in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a). Both authors independently examined the title and abstracts to exclude duplicate publications, case reports, review articles and unrelated articles. Of the remaining studies, DL and MH independently examined the full text publications to determine if they met our eligibility criteria. The authors planned to resolve any disagreements on the eligibility of studies by consulting with the third and fourth authors (MM, AS) for advice and reaching a consensus through discussion between all authors.
Data extraction and management
Should any eligible studies become available in future searches, two authors (DL, MH) will extract data using standardised data acquisition forms upon which all authors have agreed. They will resolve disagreements through discussion between all four authors. Where information is incomplete or unclear, the authors will attempt to contact the lead author of the paper where possible. The authors plan to group outcome data into those measured at up to 14 days, up to 1 month, up to 3 months, up to 6 months and up to 12 months after MRSA therapy. All authors will consider data for inclusion which was recorded at other time intervals and highlight this in the report.
Assessment of risk of bias in included studies
The authors will assess the risk of bias using methods described in theCochrane Handbook for Systematic Reviews for Interventions (Higgins 2011b). In particular each author will examine the methods to determine the adequacy of randomisation and blinding, and also whether any participants lost to follow-up are accounted for and justified. They will also seek to identify any selective reporting by comparing the full report to the protocol. In addition, each author will independently use the 'risk of bias' assessment tool available in section 8.5 of the Cochrane Handbook for Systematic Reviews for Interventions in order to judge each of the described seven domains as having low, high or unclear risk of bias (Higgins 2011b).
Measures of treatment effect
For dichotomous data (e.g. eradication achieved or not), the authors plan to analyse the data on an intention-to-treat basis, irrespective of compliance or dropout secondary to adverse effects. They will sort the data based on each possible outcome event for each treatment arm and calculate the odds ratio (OR) and its 95% CI. For continuous data, the authors plan to calculate the mean difference (MD) of effect of each variable along with its 95% CI. Where two or more studies measure the same outcome but using different scales, they aim to calculate the standardised mean difference (SMD) with its 95% CI. The authors plan to extract ordinal and count data in all forms in which they are reported and plan to analyse these as per continuous data for common outcomes; for rare outcomes they will follow the advice in section 9.2.5 of theCochrane Handbook for Systematic Reviews of Interventions (Deeks 2011). For time-to-event data (e.g. time to next exacerbation), they plan to calculate the hazard ratio (HR) at individual time points (at 14 days, then 1, 3, 6 and 12 months) along with its 95% CI.
Unit of analysis issues
Cross-over studies are not eligible for inclusion within this review since the authors are reviewing how efficacious the initial attempt at eradication of MRSA is when compared with placebo, usual treatment or no treatment. Subsequently, they aim to evaluate time until next positive MRSA culture and number of further courses of antibiotics required following each arm of therapy. The authors do not plan to include cluster-randomised controlled trials. When randomisation is performed according to patient groups, certain strains of MRSA (which may differ between communities) could potentially be over-represented in either the treatment or placebo arm and hence bias the results.
Dealing with missing data
In cases where data are missing which relate to either the review's primary or secondary outcomes, the authors will attempt to contact the primary investigator for clarification. If they are not able to contact the primary investigator, they will attempt to contact the co-investigators and sponsors.
Assessment of heterogeneity
In order to assess heterogeneity between studies the authors will use the I 2 statistic and the chi-squared test. As stated in theCochrane Handbook for Systematic Reviews of Interventions, the importance of the observed value of I 2 depends on (i) the magnitude and direction of effects and (ii) the strength of evidence for heterogeneity (e.g. P value for chi-squared) (Higgins 2011a). The authors will consider values of 0% to 40% to represent little to no heterogeneity, 30% to 60% moderate, 60% to 90% substantial and values of more than 90% as demonstrating considerable heterogeneity.
Assessment of reporting biases
The authors plan to assess for selective reporting of results by comparing (where available) the outcomes listed in the original protocol to those reported in the final paper. They will also search clinical trials registers for any completed studies relevant to our review that may not have been published. They plan to attempt to contact the primary investigators of identified trials to determine whether they are aware of any relevant unpublished data. This may help to identify some small studies which may not have reported statistically significant outcomes. The authors aim to identify publication bias with the construction of funnel plots, although they are wary of other potential causes for asymmetry.
Data synthesis
The authors aim to analyse extracted data using a fixed-effect metaanalysis unless the heterogeneity between studies is found to be substantial (more than 60%), at which point they will perform a random-effects meta-analysis.
Subgroup analysis and investigation of heterogeneity
If the authors identify a sufficient number of studies (more than 10) and also find substantial heterogeneity between studies, they will investigate this with subgroup analysis of the following:
1. eradication therapy commenced at initial acquisition versus following chronic colonisation (three or more positive cultures over a 12-month period); 2. duration of eradication therapy (up to and including 6 weeks, 7 to 12 weeks, over 12 weeks); 3. intravenous versus aerosolised versus oral administration of antibiotics; 4. efficacy of regimens which include methods for skin or nasal eradication, or both, versus those that do not.
Sensitivity analysis
Where outcome measures have been chosen based upon arbitrary values, the authors plan to re-evaluate the effect that alternative endpoints have on their findings. For instance, some studies may use a cut-off of longer than 14 days to represent successful eradication of MRSA, where the available data allows, the authors will repeat the analysis of treatment effect using different cut-offs (1, 3, 6 or 12 months). With regards to smaller studies (20 participants in each group or less) that the authors may include in the initial meta-analyses, they aim to repeat the analyses without these smaller studies to determine their effect.
R E S U L T S Description of studies Results of the search
A total of 54 references to 41 studies were identified from the CFGD Group's CF Trials Register. Seven additional studies were identified from a separate PUBMED, EMBASE and MEDLINE search. Three ongoing studies were identified from the ongoing trials registers www.clinicaltrials.gov and www.isrctn.org. These ongoing trials may be eligible for inclusion into future versions of this review: 'Early meticillin-resistant Staphylococcus aureus (MRSA) therapy in cystic fibrosis (CF)' (NCT01349192), 'Persistent meticillin-resistant Staphylococcus aureus eradication protocol' (NCT01594827) and 'Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients' (NCT01746095). Details of these studies can be found in the tables (Characteristics of ongoing studies). Please also see the PRISMA diagram (Figure 1 ).
Included studies
The authors did not identify any studies which were eligible for inclusion in the current version of this review.
Excluded studies
Of the 41 excluded studies from the results of the search of the Cystic Fibrosis and Genetic Disorders Group's CF Trials Register, 12 were pharmacokinetic studies, one was a tolerability study and the remaining 28 were excluded because the participants or interventions were not relevant to our review (See: Characteristics of excluded studies). None of the 41 studies had the primary intent of MRSA eradication in people with CF. Of the seven additional studies identified, all had relevant participants, interventions and outcomes but these were not included as they were not randomised or controlled studies. All had the primary aim of MRSA or S.aureus (one study) eradication in people with CF. Two were case reports, one of a 10-year old boy (Maiz 1998) 
Risk of bias in included studies
No studies were identified which were eligible for inclusion in this review.
Effects of interventions
D I S C U S S I O N
Summary of main results
Although MRSA is an important emerging pathogen in CF respiratory illness, there is no widely accepted consensus for its optimal management. The broad search terms used in this review identified a large number of studies listed on the Cochrane CFGD Group's CF Trials Register, unfortunately none of them were relevant or eligible for inclusion. Most of the studies identified dealt primarily with P. aeruginosa treatment in CF and not with MRSA.
Overall completeness and applicability of evidence
There are currently three ongoing prospective studies awaiting completion, which will potentially be eligible for inclusion in future versions of this review. One study examines the eradication of early MRSA acquisition, whilst the other two examines management of persistent infection (see Characteristics of ongoing studies). One of these is currently recruiting participants and is estimated to complete in March 2015 (NCT01594827) whilst the other two studies have completed patient enrolment and results are awaited (NCT01349192 and NCT01746095). All three studies will compare an active treatment group to an observational/ placebo group.
Quality of the evidence
The available evidence for this review is poor, with no published randomised controlled trials and only a few observational or retrospective studies at present.
Potential biases in the review process
One of the co-authors of this review (MM) is the lead investigator of one of the ongoing clinical trials (NCT01349192).
Agreements and disagreements with other studies or reviews
Various strategies have been proposed for the eradication of MRSA when isolated from CF respiratory samples. It has become apparent from this review that these are based on anecdotal evidence or, at best, a small number of observational studies involving small numbers of participants. The authors identified seven non-randomised and non-controlled studies; three in paediatric participants (age range 1 to 16 years), two in adults (age range 22 to 36 years) and two in mixed paediatric and adult groups. With the exception of Maiz 1998 (a case report on one 10-year old boy), and Dalbøge 2013 (a cohort study which reports on efficacy of S.aureus eradication, where only 0.3% of subjects were MRSA positive), the remaining five studies reported successful eradication of MRSA in, at least a proportion of, their participants (Garske 2004; Macfarlane 2007; Serisier 2004; Solis 2003; Vanderhelst 2013) . Whilst in the Maiz 1998 case report MRSA was not eradicated after the 17-month treatment with daily continuous inhaled vancomycin, the authors did report improvements in lung function and symptom score in the child. The Vanderhelst 2013 study reported a non-statistically significant trend in improvement of FEV1% in the 11 patients they studied, after successful eradication of MRSA. The largest cohort study (Dalbøge 2013) successfully eradicated Staphylococcus aureus from the sputum samples of the 65 patients they treated, and reported a statistically significant median (range) improvement in FEV1% predicted of 3.3% (−25% to 36%, p<0.0001). However, they did not differentiate between those patients who grew MSSA or those who grew MRSA from their sputum. This is contradictory to two other studies, which reported no significant differences in lung function between participants who were successfully eradicated when compared to those who were not (Garske 2004; Solis 2003) ; however, this may be because the numbers were too small to detect a difference. The final two studies reported successful eradication of MRSA, Macfarlane 2007 (in 94% of patients) and Serisier 2004 (in one 28-year old), but did not report on lung function or patient clinical status during or following eradication.
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is currently no published evidence from randomised controlled trials to support any one eradication regimen over another. While there are reports of successful eradication in those with CF, there is considerable uncertainty whether this is associated with patient benefit.
Implications for research
This review has highlighted the lack of evidence behind the present management of MRSA respiratory infections in CF and emphasizes the need for well-designed, adequately-powered trials with long-term follow-up in order to address this.
These will need to address the questions. The published reports of the two ongoing studies identified are keenly awaited and the authors look forward to assessing the published data of these for inclusion into a future update of this review.
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The authors would like to thank Nikki Jahnke and Tracey Remmington for all their support with the development of this review. We would also like to thank Natalie Hall for her help with the literature searches. 7. females of childbearing potential must agree to practice 1 highly effective method of birth control, including abstinence. Note: highly effective methods of birth control are those, alone or in combination, that result in a failure rate less than 1% per year when used consistently and correctly. Female participants who utilize hormonal contraceptives as a birth control method must have used the same method for at least 3 months before study dosing. If the participant is using a hormonal form of contraception, she will be required to also use barrier contraceptives as rifampin can affect the reliability of hormone therapy. Barrier contraceptives such as male condom or diaphragm are acceptable if used in combination with spermicides.
R E F E R E N C E S
References to studies excluded from this review
Interventions
Treatment group: 28-day course of inhaled vancomycin for inhalation (250 mg twice-a-day) plus oral rifampicin and oral TMP/SMX Control group: taste-matched inhaled placebo (sterile water) plus oral rifampicin and oral TMP/SMX In addition, both groups will receive oral rifampin, a second oral antibiotic (TMP-SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes 
NCT01746095
Trial name or title Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients Methods Randomised, double-blind, placebo-controlled trial. Duration 28 days with additional 56 days follow up. There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) participants. In Cohort 1, participants will be randomized to receive the 32 mg dose of AeroVanc twice daily or placebo twice daily. Prior to starting enrolment in Cohort 2, a safety evaluation will be carried out by the DMC based on treatment data from the first 20 participants in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg twice daily. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg twice daily), or reduced to 16 mg twice daily, depending on the outcome of the DMC's safety evaluation
